🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the battle against drug-resistant strains of the bacteria, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are on the rise around the world, with estimates suggesting in excess of 82 million new cases annually. Notably increased rates are seen in the African continent and countries within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The authorization of novel therapies for gonorrhoea is an significant and necessary development in the reality of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs currently available.”

Health officials are deeply concerned about the surge in antibiotic-resistant strains. The World Health Organization has listed it as a "priority pathogen". Recent surveillance showed that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Drugs Gain Approval

Zoliflodacin, marketed under the name a brand name, was authorized by the US Food and Drug Administration in mid-December for combating gonorrhoea. This disease can lead to major issues, including infertility. Scientists anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This medication, which is also used to treat urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin emerged from a unique collaborative effort for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This milestone marks a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Research Study Data and Worldwide Availability

According to data published in a prominent scientific publication, zoliflodacin eradicated the vast majority of uncomplicated infections. This establishes an similar efficacy with the existing first-line therapy, which combines an injection and a pill. The trial enrolled over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the rights to license and sell the drug in many developing nations.

Doctors on the front lines have expressed hope. The availability of a easy-to-administer therapy like this is seen as a "critical tool" for gonorrhoea control. This is viewed as crucial to reduce the burden of the illness for individuals and to halt the transmission of extremely resistant gonorrhoea globally.